Subscribe
shutterstock_2169738405_t_schneider
T. Schneider / Shutterstock.com
21 July 2022AmericasStaff writer

Generic maker pays $145m to settle antitrust suit

California company resolves pay-for-delay issue over opioids | Allegations were brought by direct purchasers eight years ago.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Irish pharma company prevails in US pay-for-delay case
5 July 2022   The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.
Big Pharma
Endo, Impax face class-action over antitrust claims
7 June 2021   Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.


Editor's picks

AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

Editor's picks

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025

More on this story

Big Pharma
Irish pharma company prevails in US pay-for-delay case
5 July 2022   The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.
Big Pharma
Endo, Impax face class-action over antitrust claims
7 June 2021   Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.

More on this story

Big Pharma
Irish pharma company prevails in US pay-for-delay case
5 July 2022   The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.
Big Pharma
Endo, Impax face class-action over antitrust claims
7 June 2021   Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.

More features

Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
USPTO speeds up patent issuance amid widespread agency changes
Lathrop GPM adds portfolio management specialist
Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug
Failure to make findings of fact adds twist to battle over Eliquis in Ireland
Novo Nordisk, Bayer, GSK among giants accused in drug delivery suits